$4.02
1.52% yesterday
NYSE, Oct 23, 10:00 pm CET
ISIN
US05380C1027
Symbol
RCEL

AVITA Therapeutics Stock price

$4.02
-1.43 26.24% 1M
-5.72 58.73% 6M
-8.78 68.59% YTD
-6.37 61.31% 1Y
-0.83 17.11% 3Y
-19.55 82.94% 5Y
-3.98 49.75% 10Y
-20.98 83.92% 20Y
NYSE, Closing price Thu, Oct 23 2025
+0.06 1.52%
ISIN
US05380C1027
Symbol
RCEL
Industry

Key metrics

Basic
Market capitalization
$107.0m
Enterprise Value
$133.5m
Net debt
$26.5m
Cash
$15.7m
Shares outstanding
26.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.4 | 1.4
EV/Sales
1.8 | 1.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
5.6%
Return on Equity
-1,374.3%
ROCE
-4,110.2%
ROIC
612.5%
Debt/Equity
-3.3
Financials (TTM | estimate)
Revenue
$74.9m | $79.0m
EBITDA
$185.5m | $-31.7m
EBIT
$183.7m | $-36.8m
Net Income
$-51.6m | $-28.4m
Free Cash Flow
$-42.0m
Growth (TTM | estimate)
Revenue
38.3% | 22.9%
EBITDA
448.5% | 42.3%
EBIT
440.2% | 34.3%
Net Income
-3.5% | 54.1%
Free Cash Flow
27.8%
Margin (TTM | estimate)
Gross
392.2%
EBITDA
247.7% | -40.1%
EBIT
245.4%
Net
-68.9% | -36.0%
Free Cash Flow
-56.0%
More
EPS
$-2.0
FCF per Share
$-1.6
Short interest
12.3%
Employees
260
Rev per Employee
$250.0k
Show more

Is AVITA Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,021 stocks worldwide.

AVITA Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

10x Buy
77%
1x Hold
8%
2x Sell
15%

Analyst Opinions

13 Analysts have issued a AVITA Therapeutics forecast:

Buy
77%
Hold
8%
Sell
15%

Financial data from AVITA Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
75 75
38% 38%
100%
- Direct Costs -219 -219
3,164% 3,164%
-292%
294 294
525% 525%
392%
- Selling and Administrative Expenses 88 88
10% 10%
118%
- Research and Development Expense 22 22
2% 2%
29%
186 186
448% 448%
248%
- Depreciation and Amortization 1.79 1.79
136% 136%
2%
EBIT (Operating Income) EBIT 184 184
440% 440%
245%
Net Profit -52 -52
3% 3%
-69%

In millions USD.

Don't miss a Thing! We will send you all news about AVITA Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AVITA Therapeutics Stock News

Neutral
GlobeNewsWire
8 days ago
VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his posi...
Neutral
GlobeNewsWire
8 days ago
Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Avita (RCEL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Avita and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Neutral
GlobeNewsWire
15 days ago
Avita revealed a six-month backlog of unpaid Recell claims due to CMS pricing delays, hurting demand and driving shares down 21% to $4.25 on August 8, 2025
More AVITA Therapeutics News

Company Profile

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

Head office United States
CEO James Corbett
Employees 260
Founded 1992
Website www.avitamedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today